# Biocodex

> Biocodex is a VC fund in San Bruno backing Health Care, Biotechnology and Biopharma. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: San Bruno, United States
- Total investments: 7
- Last investment: Nov 2025
- Lead investor: 29%
- Last updated: Aug 2026

Biocodex is a VC fund in San Bruno focused on Health Care and Biotechnology. An International Pharmaceutical Company.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 29% |
| Biotechnology | 2 | 29% |
| Biopharma | 1 | 14% |
| Pharmaceutical | 1 | 14% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 1 | 14% |
| Series B | 1 | 14% |
| Post-IPO Equity | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| MaaT Pharma | MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has alreadyachieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. | $10.6M | Post-IPO Equity | Nov 13, 2025 |  |
| Exeliom | Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $3.3M | Series A | Oct 21, 2025 |  |
| MaaT Pharma | MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has alreadyachieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. | $14M | Post-IPO Equity | Mar 27, 2025 |  |
| MaaT Pharma | MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has alreadyachieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. | $19.8M | Post-IPO Equity | May 15, 2024 |  |
| Exeliom | Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $8.7M | Series A | Jun 30, 2023 |  |
| MaaT Pharma | MaaT Pharma, a clinical stage company, has established the most complete approach to restoring patient-microbiome symbiosis to improve survival outcomes in life-threatening diseases. Committed to treating a range of cancers and Graft-versus-Host-Disease, a serious complication of allogeneic stem cell transplantation, MaaT Pharma has alreadyachieved proof of concept in acute myeloid leukemia patients. Supporting the further expansion of our pipeline into improving outcomes of immunotherapy in solid tumors, we have built a powerful discovery and analysis platform, GutPrint®, to evaluate drug candidates, determine novel disease targets and identify biomarkers for microbiome-related conditions. | $19.8M | Series B | Feb 05, 2020 |  |
| Exeliom | Exeliom is a clinical-stage biopharmaceutical company tackling the use of commensal bacteria as drugs. Their mission is to harness the therapeutic potential of gut microbiota to enable people to lead longer and healthier lives. They are committed to developing the next generation of probiotics: innovative microbial therapies.Exeliom develops anew class of medicines called Live Biotherapeutics based on their growing understanding of the central role of the microbiota in the immune system.The company was founded in 2016 and is headquartered in Dijon, France. | $7.7M | Series A | Jul 06, 2018 |  |

7 of 7 investments shown.

## Co-investors
- [Auriga Partners](https://shizune.co/investors/profile/auriga-partners) — VC Fund, 2 deals together
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 2 deals together
- [Seventure Partners](https://shizune.co/investors/profile/seventure-partners) — VC Fund, 2 deals together
- [UI Investissement](https://shizune.co/investors/profile/ui-gestion) — VC Fund, 2 deals together
- [Cap Innov'Est](https://shizune.co/investors/profile/cap-innovest) — VC Fund, 1 deal together
- [Capital Grand Est](https://shizune.co/investors/profile/capital-grand-est) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Biocodex invest in?

Biocodex invests primarily in Health Care, Biotechnology and Biopharma startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Biocodex last invest?

The most recent investment recorded for Biocodex closed in Nov 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co